Atlanta Dermatologists Also Treat Rare Skin Cancers

skin cancer treatment atlantaOne in five Americans will develop skin cancer over the course of a lifetime. Skin cancer is unique as it comes in a variety of types, shapes, and sizes. Most people have probably heard of melanoma, which is considered the most serious and dangerous type of skin cancer that usually appears as a dark black or brown lesion. Other frequently discussed skin cancers include basal cell carcinoma and squamous cell carcinoma, which are easily treatable.

Dermatology Associates of Atlanta also treats patients with more rare skin cancers that can show different warning signs than the typical sore, lesion, and scaling skin symptoms.  Rare skin cancers include dermatofibrosarcoma protuberans (DFSP), merkel cell carcinoma, and sebaceous carcinoma. Warning signs may include the appearance of scar or sty, but patients do not always consider these changes as signs of skin cancer. That’s why our board certified dermatologists recommend patients getting an annual skin check to prevent skin cancers from going undiagnosed in the early stages. In addition to a thorough skin check, our dermatologists suggest consulting with them anytime you notice an unusual skin lesion appear.

Our Skin Cancer Center treats skin cancer with several different methods including Mohs surgery: the most technologically advanced treatment that precisely removes cancer one tissue layer at a time. This method of surgery is highly effective, especially for rare cancers that may occur in sensitive areas such as the face, because it lowers the chance of regrowth and disfigurement.  Other skin cancer treatments our board certified dermatologists frequently use include photodynamic therapy, topical chemotherapy, cryosurgery, and laser treatments.

For more information about skin cancer and the available skin cancer treatments, please call for an appointment today. Be sure to connect with us on Facebook, Twitter, Google + and Pinterest for the latest dermatological news and information.